



Role of the gut–skin axis in IgE-mediated food allergy and atopic diseases

Noor Hidayatul Aini Suaini^a, Kewin Tien Ho Siah^{b,c},
and Elizabeth Huiwen Tham^{a,d,e,f}

Purpose of review

In recent years, landmark clinical trials investigating the role of early oral exposure to food antigens for food allergy (FA) prevention have highlighted the importance of immunoregulatory pathways in the ‘gut–skin axis’. This review highlights recent literature on the mechanisms of the immune system and microbiome involved in the gut–skin axis, contributing to the development of atopic dermatitis (AD), FA, allergic rhinitis (AR) and asthma. Therapeutic interventions harnessing the gut–skin axis are also discussed.

Recent findings

Epicutaneous sensitization in the presence of AD is capable of inducing Th2 allergic inflammation in the intestinal tract and lower respiratory airways, predisposing one to the development of AR and asthma. Probiotics have demonstrated positive effects in preventing and treating AD, though there is no evident relationship of its beneficial effects on other allergic diseases. Prophylactic skin emollients use has not shown consistent protection against AD, whereas there is some evidence for the role of dietary changes in alleviating AD and airway inflammation. More randomized controlled trials are needed to clarify the potential of epicutaneous immunotherapy as a therapeutic strategy for patients with FA.

Summary

The growing understanding of the gut–skin interactions on allergic disease pathogenesis presents novel avenues for therapeutic interventions which target modulation of the gut and/or skin.

Keywords

allergic diseases, epicutaneous immunotherapy, gut–skin axis, microbiome, probiotics

INTRODUCTION

As researchers gain a better understanding of multi-omic interactions in disease pathogenesis as well as the immunomodulatory effects of the host microbiome on distant organ sites, interdisciplinary fields in systems biology such as the gut–lung, gut–skin and gut–brain axes in health and disease are also growing [1]. Recent advancements in sequencing techniques, supercomputing capabilities and bioinformatics have also propelled research on the human microbiome and its role in human health and disease. There is now a rich body of evidence demonstrating the role of the gut–skin axis in the pathogenesis and treatment of allergic diseases. Cross-sectional studies have described differences in microbiota patterns in diseased vs healthy states [2^{*,3**}]; and others have observed longitudinal divergence of microbiota maturation in early life in relation to subsequent allergic disease outcomes [4^{**}].

This review, therefore, aims to summarize the latest evidence on immunological and microbiota interactions between the gastrointestinal system

and the skin in the pathogenesis of atopic diseases (atopic dermatitis (AD), food allergy (FA), allergic rhinitis (AR) and asthma), and will discuss strategies which harness the gut–skin axis for preventive and therapeutic purposes.

^aSingapore Institute for Clinical Sciences (SICS), Agency for Science, Technology and Research (A*STAR), ^bDivision of Gastroenterology & Hepatology, University Medicine Cluster, National University Hospital, ^cDepartment of Medicine, Yong Loo Lin School of Medicine, ^dDepartment of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore (NUS), ^eKhoo Teck Puat-National University Children's Medical Institute, National University Health System (NUHS) and ^fHuman Potential Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

Correspondence to Dr Elizabeth Huiwen Tham, Division of Allergy & Immunology, Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, Level 12 NUHS Tower Block, Singapore 119228, Singapore. Tel: +65 6772 3394; e-mail: paethe@nus.edu.sg

Curr Opin Gastroenterol 2021, 36:000–000

DOI:10.1097/MOG.0000000000000780

KEY POINTS

- The gut–skin axis plays a role in the development of allergic diseases via the immunological and microbiome interaction between the gastrointestinal system and the skin.
- Epicutaneous sensitization in presence of atopic dermatitis is able to trigger systemic Th2 allergic inflammation in the intestinal tract and lower respiratory airways, thereby, potentially increasing the risk of asthma and allergic rhinitis.
- Randomized controlled trials on probiotics as a standalone or add-on therapy have demonstrated promising beneficial effects as a preventive and treatment strategy for atopic dermatitis, but not for food allergy, asthma or allergic rhinitis.
- Current evidence supports epicutaneous immunotherapy as a safe and well-tolerated treatment for food allergy given its long-lasting sustained unresponsiveness effects compared to other immunotherapies and side effects limited to the local patch site.
- Further research into mechanistic studies to extend our knowledge and understanding of the underlying mechanisms of the gut–skin axis are necessary in the development of new therapeutic targets.

GUT–SKIN AXIS IN PATHOGENESIS OF ALLERGIC DISEASES

Herein, we present two mechanisms associated with the gut–skin axis in the development of allergic diseases – (i) the immunological crosstalk between the gut and skin and (ii) the gut–skin microbiome. An illustration of the mechanisms involved are depicted in Fig. 1 (Image created with BioRender).

Gut–skin immunological crosstalk

Defects in the skin barrier contributing to AD development are thought to be crucial in inducing epicutaneous sensitization to food allergens. This represents the first cascade in paving the way to development of other allergic diseases such as asthma and AR in a phenomenon known as the ‘atopic march’. The mechanisms through which antigen sensitization in the skin can influence allergic inflammation in the gut and airways are still unclear. However, thymic stromal lymphopoietin (TSLP), interleukin (IL)-33 and IL-25 are some of the key epithelial-derived cytokines influencing the cascade of immunological events in eliciting such allergic responses [5,6].

The dual allergen exposure hypothesis posits that children with defective skin barrier function and/or AD are more likely to become sensitized to

food allergens and are also more likely to become clinically food allergic; early oral allergen exposure (4–6 months) prior to acquiring sensitization is, therefore, crucial for tolerance induction [7[■],8]. A randomized controlled trial (RCT) carried out in Japanese new-borns showed a protective effect against cow’s milk allergy with daily ingestion of cow’s milk formula between 1 and 2 months of age compared to the avoidance group (breastfeeding supplemented with soy formula). Participants, however, may have had some exposure to cow’s milk formula prior to 1 month to supplement breastfeeding. Conversely, another RCT also carried out in Japan showed avoidance of cow’s milk formula for at least the first 3 days of life to be protective against cow’s milk sensitization in infants with a family history of atopy [9[■]]. These studies suggest that the timing of introduction of cow’s milk formula supplementation may be critical for these high-risk infants. Clinical studies have also shown that continued skin exposure to food allergens such as peanut oil-containing emollients result in a higher risk of peanut allergy [10]. Food sensitization through the skin is possible through a disrupted skin barrier following the activation of mast cells, type 2 innate lymphoid cells, and IL-33 signalling. TSLP, an epithelial cytokine, is mainly expressed by epithelial cells of the skin, lungs, and intestine [11[■]] and mediates type 2 inflammation. Increased TSLP-elicited basophils in the skin were detected in an ovalbumin (OVA)/peanut sensitized AD murine model subjected to intragastric antigen challenge. It is thought that Th2-dependent cytokine responses were activated, increasing serum IgE levels, leading to the accumulation of mast cells in the intestine and resulting in Immunoglobulin E (IgE)-mediated FA [12].

In contrast, gut mucosal exposure to food antigens induce oral tolerance through differentiation of naive T cells into $\alpha 4\beta 7$ + gut homing T cells, mediated by antigen-presenting cells in the gut mucosa [13]. This is followed by elaboration of Foxp3+ Tregs, IL-10 and TGF- β , which inhibit Th2 dependent allergic responses, mast cell degranulation and increase IgG4 production [14]. A loss of the gut–skin immunological equipoise thus occurs in the face of AD skin inflammation, skewing the balance towards food sensitization and clinical FA, particularly if timely oral tolerance does not occur. These mechanisms are targeted for FA prevention through early introduction of allergenic foods and will be discussed in a later section.

Epicutaneous sensitization on barrier-disrupted skin is postulated to be able to trigger systemic Th2 allergic inflammation in distant sites such as the intestinal tract and lower respiratory airways [15].




FIGURE 1. The role of gut-skin axis in sensitization and oral tolerance: Defects in the skin lead to the introduction of food allergens to antigen-presenting cells (APCs), assisted by skin microbiome and bacterial toxins. This leads to induction of B cells that produce TSLP and other IL-33 and IL-25 that stimulates generation of mast cells as well as type 2 T helper (Th2) dendritic cells (DCs) that secrete IL-4, IL-13 and IL-6 in order to stimulate the generation of Th2-skewed effector T cells. Th2 CD4⁺ T cells secrete IL-4, inducing IgE production by B cells. In the gastrointestinal tract, macrophages, CX3CR1⁺ APCs, or CD103⁺ DCs ensure maintenance of tolerance through the development of IL-10-producing Tregs and IgA-secreting B cells. In the induction of oral tolerance, food antigen, and gut microbiota stimulate DCs to produce IL-10 and to induce regulatory T cells. Oral tolerance has been stipulated to play a protective role in allergic diseases such as asthma and allergic rhinitis. Image created with BioRender.

Overexpression of TSLP, a key mediator by which epicutaneous sensitization can trigger and maintain chronic lung inflammation as well as intestinal FA [16], elicits allergic sensitization and bronchial hyper-responsiveness [15]. On the contrary, reduced TSLP levels attenuate Th2 responses and airway inflammation [15]. Mice epicutaneously exposed to the OVA antigen in the presence of TSLP have been shown to develop severe airway inflammation upon airway challenge [17]. IL-33 is also a crucial cytokine in the gut-skin-lung cross talk involved in asthma pathogenesis. Both *IL-33* and *ST2/IL1RL1* (IL-33 receptor through which IL-33 induce its signalling) genes have been identified as asthma susceptibility loci [18]. Mice exposed to recombinant IL-33 and OVA through the skin showed involvement of IL-33 in development of allergen sensitization leading to subsequent pulmonary reactions as indicated by an increase in bronchial alveolar lavage cellularity and IgE levels [6].

Involvement of the gut and skin microbiome

Gut and skin microbiota also play a key role in the gut-skin immunological pathways implicated in the pathogenesis of allergic disorders. Gut dysbiosis in early life has been identified as a potential marker of AD, FA and allergic airway disease.

Food allergy and atopic dermatitis

An altered gut microbiota composition has been associated with FA. For example, antibiotic usage reduces gut microbiota diversity and has been associated with the development of FA [19].

In AD, studies have also shown that gut dysbiosis appears to precede AD onset, as distinct differences have been observed in the early life gut microbiome of those who develop AD and those who do not. Gut microbiota of infants with AD had higher abundance of *Enterobacteriaceae* (*Escherichia coli* and *Klebsiella pneumoniae*) and lower abundance

of *Bacteroidaceae* family (*B. fragilis*) at 3 weeks of life [20]. Mechanistically, this may occur through the 'leaky gut' / 'epithelial barrier' hypothesis, whereby the disrupted epithelial barrier increases epithelial permeability, enhancing translocation of gut microbiota into the bloodstream and skin, leading to systemic inflammation [21,22[†]].

Asthma and allergic rhinitis

Studies have also linked gut dysbiosis in early life to an increased asthma risk later in life. Lower gut microbiome diversity (*Rothia*, *Faecalibacterium*, *Lachnospira*, and *Veillonella*) in the first month of life was observed in children who developed asthma at school age compared to nonasthmatic children [23]. Correspondingly, OVA/alum-sensitized adult offspring of mice colonized with *Rothia*, *Faecalibacterium*, *Lachnospira*, and *Veillonella* also showed attenuated allergic airway inflammation, evident by the lower number of immune cells detectable in the bronchoalveolar lavage fluid [23,24].

Adults with AR were also reported to have a markedly reduced microbial diversity and alteration

in the abundance of certain microbes (*Clostridium hylemonae*, *Ruminococcus gnavus*, and *Acidaminococcus intestini* species) compared to controls [25^{††}]. *R. gnavus* has previously been associated with respiratory allergies – *R. gnavus*-infected mice displayed increased airway hyperresponsiveness and histologic airway inflammation after sensitization and challenge with OVA [26]. In mice, a significantly increased abundance of *R. gnavus* in the AR group compared to controls was observed. Taken together, there is increasing evidence that there is an interplay between gut and lung for maintenance of airway immune homeostasis [27].

GUT–SKIN AXIS IN THERAPEUTIC INTERVENTIONS

Therapeutic strategies which harness the immunological interactions between the gut and skin are now being developed for prevention and management of AD, FA and allergic airway diseases. A summary of the interventions is provided in Table 1.

Table 1. Summary of the gut–skin axis and its potential therapeutic strategies in allergic diseases

Gut skin immunology	Refer to Fig. 1
Gut skin microbiome	AD: ↑ abundance of <i>Enterobacteriaceae</i> (<i>E. coli</i> and <i>K. pneumoniae</i>), ↓ abundance of <i>Bacteroidaceae</i> family (<i>B. fragilis</i>) in AD infants. FA: ↓ in gut microbiota diversity associated with ↑ food allergy. Asthma: ↓ gut microbiome diversity (<i>Rothia</i> , <i>Faecalibacterium</i> , <i>Lachnospira</i> , and <i>Veillonella</i>) in children with asthma. AR: ↓ microbial diversity and changes in abundance of certain microbes (<i>Clostridium hylemonae</i> , <i>Ruminococcus gnavus</i> , and <i>Acidaminococcus intestini</i> species) in adults with AR.
Prevention strategies	
Probiotics	AD: Combination of maternal probiotic supplementation during pregnancy and lactation, alongside concurrent infant supplementation ↓ AD risk. FA: Human studies mostly inconclusive due to methodological differences/flaws. Maternal carriage of <i>Prevotella copri</i> during pregnancy associated with ↓ infant FA. Asthma: No evidence of a significant association between supplementation and asthma. AR: Insufficient evidence of a beneficial effect in preventing development of allergic rhinitis.
Dietary patterns	AD: Microbiota changes from birth up till when solid food is introduced, thereafter diet plays a bigger role. Reduced consumption of fruit and vegetables, alongside high consumption of fatty acids, have been linked to AD risk. Asthma: Short-chain fatty acids protect against development of allergic airway inflammation. Butyrate producing microbiota associated with ↑ asthma risk.
Skin care emollients	AD: No significant effect of emollients and different skin interventions on reducing risk of atopic dermatitis. FA: Lack of evidence on pooled data of food sensitization and food allergy outcomes.
Treatment strategies	
Epicutaneous immunotherapy	FA: Insufficient RCTs to conclude on potential of EPIT as superior to other immunotherapies. Treatment well-tolerated apart from moderate local skin reactions.
Probiotics	AD: Probiotic mixture comprising of <i>B. animalis subsp. lactis</i> CECT 8145, <i>B. longum</i> CECT 7347, and <i>L. casei</i> CECT 9104, effective in AD treatment. ↓ in <i>Faecalibacterium</i> concentrations with corresponding ↓ in SCORAD scores. AD: Emollients supplemented with probiotic strains improved SCORAD and TEWL.

†, increased/high; ↓, reduction/low; AD, atopic dermatitis; AR, allergic rhinitis; EPIT, epicutaneous immunotherapy; FA, food allergy; SCORAD, SCORing atopic dermatitis; RCTs, randomized controlled trials; TEWL, transepidermal water loss.

Prevention strategies

The use of probiotics, diet and skin care interventions have been suggested to have beneficial effects in preventing AD and FA.

Probiotics

Probiotics are live microorganisms thought to provide a health benefit by modulating the composition of the gut microbiota, exerting systemic immunomodulatory effects in other organ systems beyond the gut [28]. RCTs have demonstrated a role for probiotics and/or prebiotics in AD prevention [29[¶]]. In a systematic review of 21 studies, the most effective approach to reduce AD risk was suggested to be a combination of maternal probiotic supplementation during pregnancy as well as lactation, alongside concurrent supplementation duration of between 6 months and 2 years in their offspring [30]. However, the efficacy of probiotics in RCTs in FA prevention remains contentious [31^{¶¶}]. Several systematic reviews and meta-analyses of randomized control studies on probiotic formulations or specific bacterial strains for FA prevention were mostly inconclusive due to methodological flaws and imprecise estimated effects inherent in these studies which preclude definitive recommendations at this time [31^{¶¶},32]. Recent evidence however has shown maternal carriage of *Prevotella copri*, responsible for producing short-chain fatty acids (SCFAs) and endotoxins, to be associated with a reduction in FA risk [33^{¶¶}]. This suggests a possible role of antenatal maternal gut microbiota modification to ameliorate FA in the offspring.

A meta-analysis of 17 RCTs carried out in 5264 children did not demonstrate sufficient evidence that probiotics are able to prevent the development of AR [34]. Nonetheless, a probiotic mixture of *Bifidobacterium longum* IM55 and *Lactiplantibacillus plantarum* IM76, appeared to alleviate AR symptoms in both human and mice studies. In a double-blind, RCT, total nasal symptom scores and rhinitis control assessment scores in subjects with perennial AR improved following administration of probiotics over four weeks [35].

Less is known about the role of probiotics in asthma prevention. A meta-analysis of 14 studies showed no significant association between probiotic supplementation and asthma prevention [34]. Although there was some evidence that administration of *Lactobacillus rhamnosus* in the pre/postnatal period protected against asthma compared to placebo, this effect did not remain significant in high-risk groups [34]. Larger RCTs are thus still required to demonstrate the efficacy of these interventions in humans.

Dietary patterns

Apart from probiotics, dietary factors may also play a role in modulating gut microbiota composition in relation to AD risk. Dietary patterns may alter the natural transition patterns of the infant gut microbiome and impact on allergic disease risk. The gut microbiota composition transitions gradually after birth from a predominant *Enterobacteriaceae* and *Staphylococcus* to *Bifidobacterium* and some lactic acid bacteria in early infancy and stabilizes after solid food introduction, eventually resulting in an adult-like composition consisting of bacteria in the genera *Bacteroides*, *Prevotella*, *Ruminococcus*, *Clostridium*, and *Veillonella* [36]. Thereafter, the microbiota is largely determined by dietary intake [37]. Reduced consumption of fruit [38] and vegetables [39], alongside high consumption of fatty acids, have been linked to AD risk [40[¶],41].

SCFAs are also thought to protect against the development of allergic airway inflammation [42]. Observational studies have shown lower stool SCFA levels along with butyrate producing microbiota were associated with increased asthma risk [43], whereas lower stool acetate levels were associated with wheeze [23]. Dietary interventions to increase SCFA levels may therefore be a promising approach in preventing allergic diseases.

Skin care interventions

Epicutaneous sensitization through the defective skin barrier in AD is postulated to be the major pathway through which FA develops. Therefore, it was proposed that barrier restoration interventions, such as prophylactic emollient applications in high-risk infants from birth might prevent AD and subsequent FA development. However, recent RCTs (Preventing Atopic Dermatitis and Allergies - PreventADALL and Barrier Enhancement for Eczema Prevention - BEEP) did not support the use of emollients as a preventive measure [44[¶],45[¶]]. A recent meta-analysis on 33 clinical trials also showed no significant effect of different skin interventions, which included the use of bathing practices, oils as well as moisturizers/emollients, during the first year of life in healthy infants on reducing AD risk by 1–3 years. However, the analysis was not restricted to emollients alone, and AD outcomes were measured across a wide age range [46^{¶¶}]. Pooled data on food sensitization and FA outcomes are not yet available as several of these trials are still ongoing. There thus remains a gap in the understanding of how skin emollients alone may impact epicutaneous sensitization, immunological pathways and gastrointestinal responses to food allergens, and future studies and meta-analyses could be designed to address this specific question.

Table 2. Comparisons between EPIT, OIT and SLIT

	Epicutaneous immunotherapy	Oral immunotherapy	Sublingual immunotherapy
Site	Skin	Oral	Sublingual
Mechanistic pathway	↑↑ Foxp3+, ↑ LAP+ Tregs Requires CTLA-4	↑ Foxp3+, ↑ LAP+ Tregs Requires IL-10 and CTLA-4	↑ Foxp3+ ↑ IL-10 ⁺ cells Requires IL-10
Efficacy	Moderate efficacy [53]	Most effective [52]	Less effective [54]
Safety profile	Fewer AEs than OIT and SLIT	Highest rates of AEs	Fewer AEs than OIT

AE, adverse events; CTLA-4, cytotoxic T-lymphocyte antigen 4; EPIT, epicutaneous immunotherapy; IL, interleukin; LAP, latency associated peptide; OIT, oral immunotherapy; SLIT, sublingual immunotherapy.

Treatment strategies

Apart from complete allergen avoidance, epicutaneous immunotherapy (EPIT) have been proposed as an alternative treatment approach in FA. The potential of probiotics as a preventive strategy have also prompted clinical trials to explore its potential as a standalone and/or add-on intervention in treating AD.

Epicutaneous immunotherapy

EPIT involves the administration of small amount of the allergen incorporated into patches which are placed on the skin for 8–48 h daily [47] to elicit desensitization, and to raise the threshold for allergic responses, in the allergic patient. In a recent phase 3 EPIT trial, children with peanut allergy aged 4–11 years randomized to a patch containing 250 µg of peanut protein over a 12-month treatment period, experienced higher reaction thresholds compared to children with placebo, although the study did not meet its primary efficacy outcome [48]. EPIT was generally well-tolerated apart from moderate local skin reactions [49[¶]]. Sustained unresponsiveness to peanut has also been demonstrated following two to three years of EPIT [50^{¶¶}].

The mechanisms of desensitization for EPIT differ from other approaches such as oral (OIT) and sublingual (SLIT) immunotherapy (Table 2). Although FoxP3⁺ Tregs remain central to all immunotherapy regimens, the subset of Tregs activated in EPIT differs from OIT and SLIT [51]. Levels of latency associated peptide (LAP), LAP⁺ Tregs, a late-stage Treg activation marker [52], are elevated in EPIT and OIT, whereas IL-10⁺ is induced in SLIT. EPIT-induced Tregs also require the expression of cytotoxic T-lymphocyte antigen 4 (CTLA4), a surface marker expression, involved in the natural desensitization pathway of the skin [53]. OIT requires both IL-10 and CTLA-4, whereas SLIT acts through IL-10 alone [54]. Although OIT has consistently been shown to be more efficacious, it is inundated with issues of tolerability and adverse side effects compared to EPIT [53,54]. Conversely, SLIT has fewer

adverse effects but is less efficacious than OIT and EPIT. Further RCTs in EPIT are required to ascertain whether the differences in mechanisms of desensitization may be key in bringing about a more sustained effect against further sensitizations. If so, highlighting EPIT as a novel treatment alternative that is safe and convenient in treatment of food allergies.

Probiotics

An oral probiotic mixture comprising of *B. animalis* subsp. *lactis* CECT 8145, *B. longum* CECT 7347, and *L. casei* CECT 9104, have successfully been shown to be effective in AD treatment through the modulation of the gut microbiome in humans [55[¶]]. Although there were no observable significant changes in microbial diversity, changes in several microbial species in the probiotic group have been associated with AD severity (SCORAD). In particular, a reduction in *Faecalibacterium* concentrations was observed with a corresponding decrease in SCORAD scores.

Extending these results, a systematic review on intervention studies of emollients supplemented with probiotic strains showed considerable improvement in clinical measures such as SCORAD and transepidermal water loss (TEWL), with none reporting any serious adverse events [56^{¶¶}]. However, the authors cautioned that a risk of bias assessment showed methodological concerns in several studies which may weaken the overall evidence base. Notwithstanding, current evidence on probiotics as a standalone or a supplement to existing treatment measures of AD have shown beneficial effects and a good safety profile that holds promise as future therapeutic adjuncts.

CONCLUSION

Numerous studies have shown that early life is a critical window during which gut microbiota dysbiosis and subsequent immunodysregulation may lead to the development of many allergic and/or

respiratory diseases [57]. This, therefore, represents a window of opportunity for preventive interventions. Although promising beneficial effects of microbiome-related interventions have been demonstrated in allergic disease prevention, carefully designed clinical trials are still required to assess effectiveness of these targeted treatments in various patient groups. Continued research into mechanistic studies to enhance understanding of the underlying mechanisms are also crucial in aiding the development of new therapeutic targets.

Acknowledgements

None.

Financial support and sponsorship

E.H.T. is supported by the National Medical Research Council (NMRC) Transition Award grant [MOH-TA18nov-003] from NMRC, Singapore.

Conflicts of interest

There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Arck P, Handjiski B, Hagen E, *et al.* Is there a 'gut-brain-skin axis'? *Exp Dermatol* 2010; 19:401–405.
2. Łoś-Rycharska E, Gołębiowski M, Sikora M, *et al.* A combined analysis of gut and skin microbiota in infants with food allergy and atopic dermatitis: A Pilot Study. *Nutrients* 2021; 13:1682–1701.
- In this study, the authors explored the effects of skin and gut microbiota of infants under six months of age with atopic dermatitis and food allergy.
3. Hu C, Van Meel ER, Medina-Gomez C, *et al.* A population-based study on associations of stool microbiota with atopic diseases in school-age children. *J Allergy Clin Immunol* 2021; 148:612–620.
- This study is the latest study to investigate the association of stool microbiota with allergic diseases in 10-year old children.
4. Galazzo G, Van Best N, Bervoets L, *et al.* Development of the microbiota and associations with birth mode, diet, and atopic disorders in a longitudinal analysis of stool samples, collected from infancy through early childhood. *Gastroenterology* 2020; 158:1584–1596.
- This longitudinal study of children from 5 weeks through to 6-11 years demonstrated changes in microbiota maturation and its associations with allergic diseases. Various environmental, lifestyle and dietary factors such as breastfeeding and birth mode were also included in their analyses.
5. Han H, Roan F, Johnston LK, *et al.* IL-33 promotes gastrointestinal allergy in a TSLP-independent manner. *Mucosal Immunol* 2018; 11:394–403.
6. Han H, Ziegler SF. Intradermal administration of IL-33 induces allergic airway inflammation. *Sci Rep* 2017; 7:1706–1713.
7. Sakihara T, Otsuji K, Arakaki Y, *et al.* Randomized trial of early infant formula introduction to prevent cow's milk allergy. *J Allergy Clin Immunol* 2021; 147:224–232. e8.
- This study provides supporting evidence for the early introduction of cow's milk formula in preventing cow's milk allergy.
8. Lack G. Epidemiologic risks for food allergy. *J Allergy Clin Immunol* 2008; 121:1331–1336.
9. Urashima M, Mezawa H, Okuyama M, *et al.* Primary prevention of cow's milk sensitization and food allergy by avoiding supplementation with cow's milk formula at birth: a randomized clinical trial. *JAMA Pediatr* 2019; 173:1137–1145.
- This study provides supporting evidence for the avoidance of cow's milk formula in the first 3 days of life in preventing cow's milk sensitization.

10. Benor S, Shani N, Etkin S, *et al.* Epicutaneous exposure to peanut oil induces systemic and pulmonary allergic reaction in mice. *Int Arch Allergy Immunol* 2019; 179:187–191.
11. Van Splunter M, Liu L, Van Neerven RJ, *et al.* Mechanisms underlying the skin-gut cross talk in the development of ige-mediated food allergy. *Nutrients* 2020; 12:3830–3849.
- This review gives further insights into the mechanisms of the gut-skin axis involved in food allergy.
12. Noti M, Kim BS, Siracusa MC, *et al.* Exposure to food allergens through inflamed skin promotes intestinal food allergy through the thymic stromal lymphopoietin-basophil axis. *J Allergy Clin Immunol* 2014; 133:1390–1399. e1–6.
13. Chan SM, Turcanu V, Stephens AC, *et al.* Cutaneous lymphocyte antigen and alpha4beta7 T-lymphocyte responses are associated with peanut allergy and tolerance in children. *Allergy* 2012; 67:336–342.
14. Weiner HL, Da Cunha AP, Quintana F, Wu H. Oral tolerance. *Immunol Rev* 2011; 241:241–259.
15. Zhu TH, Zhu TR, Tran KA, *et al.* Epithelial barrier dysfunctions in atopic dermatitis: a skin-gut-lung model linking microbiome alteration and immune dysregulation. *Br J Dermatol* 2018; 179:570–581.
16. Leyva-Castillo JM, Hener P, Jiang H, Li M. TSLP produced by keratinocytes promotes allergen sensitization through skin and thereby triggers atopic march in mice. *J Invest Dermatol* 2013; 133:154–163.
17. Han H, Xu W, Headley MB, *et al.* Thymic stromal lymphopoietin (TSLP)-mediated dermal inflammation aggravates experimental asthma. *Mucosal Immunol* 2012; 5:342–351.
18. El-Husseini ZW, Gosens R, Dekker F, Koppelman GH. The genetics of asthma and the promise of genomics-guided drug target discovery. *Lancet Respir Med* 2020; 8:1045–1056.
19. Iweala OL, Nagler CR. The microbiome and food allergy. *Annu Rev Immunol* 2019; 37:377–403.
20. Ta LDH, Chan JCY, Yap GC, *et al.* A compromised developmental trajectory of the infant gut microbiome and metabolome in atopic eczema. *Gut Microb* 2020; 12:1–22.
21. Ellis SR, Nguyen M, Vaughn AR, *et al.* The skin and gut microbiome and its role in common dermatologic conditions. *Microorganisms* 2019; 7:550–568.
22. Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? *Nat Rev Immunol* 2021. doi: 10.1038/s41577-021-00538-7 [Epub ahead of print]
- This review presents a comprehensive account of the epithelial barrier including mechanisms affecting the microbiome and its involvement in the development of allergic diseases.
23. Arrieta M-C, Stiemsma LT, Dimitriu PA, *et al.* Early infancy microbial and metabolic alterations affect risk of childhood asthma. *Sci Transl Med* 2015; 7:307ra152–1307ra.
24. Kemter AM, Nagler CR. Influences on allergic mechanisms through gut, lung, and skin microbiome exposures. *J Clin Invest* 2019; 129:1483–1492.
25. Watts AM, West NP, Zhang P, *et al.* The gut microbiome of adults with allergic rhinitis is characterised by reduced diversity and an altered abundance of key microbial taxa compared to controls. *Int Arch Allergy Immunol* 2021; 182:94–105.
- This study showed significant reduction in microbial diversity in the allergic rhinitis group compared to the control group, with enrichment of *Parabacteroides* and lower abundance of *Oxalobacter* and *Clostridiales*.
26. Chua HH, Chou HC, Tung YL, *et al.* Intestinal dysbiosis featuring abundance of *Ruminococcus gnavus* associates with allergic diseases in infants. *Gastroenterology* 2018; 154:154–167.
27. Dang AT, Marsland BJ. Microbes, metabolites, and the gut-lung axis. *Mucosal Immunol* 2019; 12:843–850.
28. Wang HT, Anvari S, Anagnostou K. The role of probiotics in preventing allergic disease. *Children* 2019; 6:24–32.
29. Tan-Lim CSC, Esteban-Ipac NaR. Recto MST, *et al.* Comparative effectiveness of probiotic strains on the prevention of pediatric atopic dermatitis: a systematic review and network meta-analysis. *Pediatr Allergy Immunol* 2021; 32:1255–1270.
- This recent systematic review presents the effects of different probiotic strains on atopic dermatitis. Mix8 (*Lactobacillus paracasei* ST11, *Bifidobacterium longum* BL999), LP (*Lactobacillus paracasei* ssp *paracasei* F19) and Mix3 (*Lactobacillus rhamnosus* GG, *Bifidobacterium animalis* ssp *lactis* Bb-12) are the top 3 probiotics found most efficacious in reducing risk of atopic dermatitis.
30. Amalia N, Orchard D, Francis KL, King E. Systematic review and meta-analysis on the use of probiotic supplementation in pregnant mother, breastfeeding mother and infant for the prevention of atopic dermatitis in children. *Australas J Dermatol* 2020; 61:e158–e173.
31. De Silva D, Halken S, Singh C, *et al.* Preventing food allergy in infancy and childhood: Systematic review of randomised controlled trials. *Pediatr Allergy Immunol* 2020; 31:813–826.
- This systematic review summarizes evidence from randomized controlled trials over the last 10 years, on the various interventions and ways of preventing food allergy.
32. Pratap K, Taki AC, Johnston EB, *et al.* A Comprehensive review on natural bioactive compounds and probiotics as potential therapeutics in food allergy treatment. *Front Immunol* 2020; 11:996–1017.

33. Vuillermin PJ, O'hely M, Collier F, *et al.* Maternal carriage of *Prevotella* during pregnancy associates with protection against food allergy in the offspring. *Nat Commun* 2020; 11:1452–1458.

This is the first human study to show an association between maternal gut microbiota during pregnancy and the offspring allergic disease. Maternal carriage of *Prevotella copri* was significantly associated with a reduction in the risk of food allergy during infancy.

34. Du X, Wang L, Wu S, *et al.* Efficacy of probiotic supplementary therapy for asthma, allergic rhinitis, and wheeze: a meta-analysis of randomized controlled trials. *Allergy Asthma Proc* 2019; 40:250–260.
35. Kang MG, Han SW, Kang HR, *et al.* Probiotic NVP-1703 alleviates allergic rhinitis by inducing IL-10 expression: a four-week clinical trial. *Nutrients* 2020; 12:1427–1440.
36. Tanaka M, Nakayama J. Development of the gut microbiota in infancy and its impact on health in later life. *Allergol Int* 2017; 66:515–522.
37. Timmerman HM, Rutten N, Boekhorst J, *et al.* Intestinal colonisation patterns in breastfed and formula-fed infants during the first 12 weeks of life reveal sequential microbiota signatures. *Sci Rep* 2017; 7:8327–8336.
38. Cepeda AM, Del Giacco SR, Villalba S, *et al.* A Traditional diet is associated with a reduced risk of eczema and wheeze in Colombian children. *Nutrients* 2015; 7:5098–5110.
39. Tanaka T, Kouda K, Kotani M, *et al.* Vegetarian diet ameliorates symptoms of atopic dermatitis through reduction of the number of peripheral eosinophils and of PGE2 synthesis by monocytes. *J Physiol Anthropol Appl Human Sci* 2001; 20:353–361.
40. De Pessemier B, Grine L, Debaere M, *et al.* Gut-skin axis: current knowledge of the interrelationship between microbial dysbiosis and skin conditions. *Microorganisms* 2021; 9:353–386.

This review gives a comprehensive account on the interplay between gut and skin microbiome in various skin conditions and the effect that diet might have in modulating the development of the diseases.

41. Devereux G, Seaton A. Diet as a risk factor for atopy and asthma. *J Allergy Clin Immunol* 2005; 115:1109–1117. quiz 18.
42. Trompette A, Gollwitzer ES, Yadava K, *et al.* Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. *Nat Med* 2014; 20:159–166.
43. Roduit C, Frei R, Ferstl R, *et al.* High levels of butyrate and propionate in early life are associated with protection against atopy. *Allergy* 2019; 74:799–809.
44. Chalmers JR, Haines RH, Bradshaw LE, *et al.* Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. *Lancet* 2020; 395:962–972.

This large randomized controlled trial presented showed no beneficial effects of daily emollient use on preventing eczema in high-risk children.

45. Skjerven HO, Rehinder EM, Vettukattil R, *et al.* Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. *Lancet* 2020; 395: 951–961.

This randomized clinical trial showed evidence, contrary to earlier studies, that atopic dermatitis was not prevented with use of bath oil and face-emollient cream.

46. Kelleher MM, Cro S, Van Vogt E, *et al.* Skincare interventions in infants for preventing eczema and food allergy: a cochrane systematic review and individual participant data meta-analysis. *Clin Exp Allergy* 2021; 51:402–418.

This latest Cochrane systematic review showed that emollient use is unlikely to reduce risk of eczema and its effect on food allergy risk is also inconclusive.

47. Esposito S, Isidori C, Pacitto A, *et al.* Epicutaneous immunotherapy in rhinoconjunctivitis and food allergies: a review of the literature. *J Transl Med* 2018; 16:329–336.
48. Fleischer DM, Greenhawt M, Sussman G, *et al.* Effect of epicutaneous immunotherapy vs placebo on reaction to peanut protein ingestion among children with peanut allergy: The PEPITES randomized clinical trial. *JAMA* 2019; 321:946–955.
49. Xiong L, Lin J, Luo Y, *et al.* The efficacy and safety of epicutaneous immunotherapy for allergic diseases: a systematic review and meta-analysis. *Int Arch Allergy Immunol* 2020; 181:170–182.

Meta-analyses from this systematic review shows promising evidence for use of epicutaneous immunotherapy in peanut allergy.

50. Brown-Whitehorn TF, De Blay F, Spergel JM, *et al.* Sustained unresponsiveness to peanut after long-term peanut epicutaneous immunotherapy. *J Allergy Clin Immunol Pract* 2021; 9:524–526.

This study showed promising results for the use of epicutaneous immunotherapy in treatment of food allergy. Sustained unresponsiveness was achieved in participants 2 to 3 years after epicutaneous immunotherapy.

51. Smeekens JM, Kulis MD. Evolution of immune responses in food immunotherapy. *Immunol Allergy Clin N Am* 2020; 40:87–95.
52. Pecora V, Valluzzi RL, Mennini M, *et al.* Debates in allergy medicine: does oral immunotherapy shorten the duration of milk and egg allergy? The pro argument. *World Allergy Org J* 2018; 11:11–17.

53. Bird JA, Sanchez-Borges M, Ansotegui IJ, *et al.* Skin as an immune organ and clinical applications of skin-based immunotherapy. *World Allergy Org J* 2018; 11:38–45.

54. Marcucci F, Isidori C, Argentiero A, *et al.* Therapeutic perspectives in food allergy. *J Transl Med* 2020; 18:302–308.

55. Climent E, Martinez-Blanch JF, Llobregat L, *et al.* Changes in gut microbiota correlates with response to treatment with probiotics in patients with atopic dermatitis. a post hoc analysis of a clinical trial. *Microorganisms* 2021; 9:854–864.

This study analyses the results from a recent clinical trial on a probiotics mixture to examine the changes in gut microbiome in the treatment group. The probiotic mixture showed improvements in SCORAD accompanied by a reduction in *Faecalibacterium* levels.

56. Ambrozej D, Kunkiel K, Dumycz K, Feleszko W. The use of probiotics and bacteria-derived preparations in topical treatment of atopic dermatitis—a systematic review. *J Allergy Clin Immunol Pract* 2021; 9:570–575. e2.

This is the first systematic review to review the evidence for the use of emollients in conjunction with probiotics as a treatment for atopic dermatitis. Current evidence on 7 studies showed positive effects of the intervention, although its safety is yet to be determined.

57. Sokolowska M, Frei R, Lunjani N, *et al.* Microbiome and asthma. *Asthma Res Pract* 2018; 4:1–9.